CSPC Pharmaceutical Group Ltd (1093)

  • Get an in-depth profile of CSPC Pharmaceutical Group Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.

Select Exchange

Symbol Exchange Currency
1093 Hong Kong HKD Delayed CHJTF OTC Markets USD Delayed 1093 Frankfurt EUR Delayed
1.0855 -0.0645 (-5.61%)
Closed EUR Disclaimer

CSPC Pharmaceutical Group Ltd Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
25147
Equity Type
ORD
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People’s Republic of China.
Contact Information
Address
Shijiazhuang,050035 China
Phone
86 31 1870 37015
Fax
86 31 1870 39608
Web
https://www.cspc.com.hk
Top Executives
Name
Age
Since
Title
Chuan Chen 57 2016 Independent Non-Executive Director
Qingxi Wang 55 2018 Executive Director
Hongguang Wang 58 2021 Independent Non-Executive Director
Chun Kwok Au 48 2021 Independent Non-Executive Director
Bo Wang 61 2012 Independent Non-Executive Director
Cheuk Kin Law 59 2021 Independent Non-Executive Director
Hao Jiang 38 2020 Executive Director
Weidong Pan 52 2006 Executive Director
Kin Man Chak 56 2005 Executive Director
Zhenguo Wang 52 2012 Executive Director
Huaiyu Wang 59 2010 Executive Director
Chunlei Li 46 2017 Executive Director & Chief Scientist
Dongchen Cai 68 1997 Executive Chairman
Cuilong Zhang 53 2018 Vice-Chairman & CEO
Quan Li 42 2022 Independent Non-Executive Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.